Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma

Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study

A Multi-Centre, Multi-country, Randomized, Double-Blind (Subject, Investigator), Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma

Inclusion Criteria:

• history of asthma for ≥ 6 months
• taking inhaled corticosteroids
• non-smoking
• Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.
• Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.
• symptomatic according to the ACQ-7

Exclusion Criteria:

• Unstable severe asthma
• Recent respiratory illness
• Presence of other respiratory disease or chronic pulmonary condition other than asthma
• Treatment with omalizumab within 4 months of study
• Recent gastrointestinal or respiratory parasitic infestation
• History of severe allergy to food or drugs

Other protocol-defined inclusion/exclusion criteria may apply